(Date:11/23/2009)...,, SANDIEGO,Nov.23/PRNewswire/--VictoryPharma,I...74;DoseCard,afurtherextensionofVictory,sNAPRELANfr...tswhorequirerelieffrommildtomoderatepainandinflamm...initisandbursitis.Itisalsodesignedforpatientssuffe...ereceivingothertherapiesandneedadditionalanti-infl...
(Date:11/23/2009)...pert says findings support link between mental and...althDay News) -- Being depressed might take as man... suggests. , However, a combination of depressi...than just depression. , Researchers came to the... survey of more than 60,000 people. During the fou...
(Date:11/23/2009)...most 20 percent get infected within one year of st...MONDAY, Nov. 23 (HealthDay News) -- As many as one...ansmitted disease (STD), many infected soon after ...ort shows. , "The high burden of STDs among tee...d study author Dr. Sami L. Gottlieb, from the divi...
(Date:11/23/2009)...Women who store fat on their waist in middle age a...hen they get older, reveals a new study from the S...blished in the scientific journal Neurology . , ...s at greater risk of dying prematurely due to a he...ior lecturer at the Sahlgrenska Academy. "If they ...
(Date:11/23/2009)...MAYWOOD, Il. -- A Loyola University Health System ...ics is morbidly obese -- approximately 100 pounds ...62.4 percent of U.S. adults with Type 2 diabetes a...ng African American adults with Type 2 diabetes, 1...besity among people with diabetes is increasing at...
Breaking Medicine News(10 mins):Health News:Victory Pharma, Inc. Announces Launch of NAPRELAN(R) Dose Card 2Health News:Depression May Up Death Risk to That of Smoking 2Health News:One in Four Teen Girls Have STDs 2Health News:One in Four Teen Girls Have STDs 3Health News:Diabetics show alarming increase in morbid obesity 2... A Lifeclinic LC300 automated blood pressure ...me talk show, The Doctors. The series airs each we...m a panel of four practicing medical professionals... on the new CBS daytime talk show, The Doctors. Th...
...ded and gsi interactive Named as Digital Marketing...TSBURGH, Pa., Dec. 16 GSI Commerce Inc. (Nasdaq: ...tichannel solutions, today announced a multiyear e...lements. Under the agreement, which runs through ...
... reach immune cells in just 4 hours , , TU...male-to-female transmission of HIV -- in which the...reach immune cells in just four hours -- has been ...tercourse, because the large HIV virus couldn,t pe...
...., Dec. 16 Third Brigade,( http://www.thirdbrigad...ion,for dynamic datacenters, today announced that ...eployed Third Brigade Deep Security for increased,...l,data resulting from nearly three quarters of a m...
...ty letter scores increased similarly in all treatm...swire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; TSX:...terim analysis for the Phase II RADICAL study (Red... study comparing reduced-fluence Visudyne(R)-Lucen...
... CeloNova BioSciences, Inc., announced,today that ...e U.S. Food and,Drug Administration (FDA) for Embo...icated for the treatment of hypervascularized tumo...l sales of,Embozene(TM) Microspheres will begin im...
Other Medicine News:Health News:Benefits of a Lifeclinic LC300 Automated Blood Pressure Monitor Recently Featured on Daytime Medical Talk Show 2Health News:GSI Commerce and GNC Corporation Extend E-Commerce Agreement Through 2017 2Health News:GSI Commerce and GNC Corporation Extend E-Commerce Agreement Through 2017 3Health News:HIV Can Penetrate a Woman's Healthy Genital Skin 2Health News:Beth Israel Deaconess Medical Center Maintains Healthy IT Servers With Third Brigade 2Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 2Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 3Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 4Health News:QLT announces interim results of radical study evaluating Visudyne combination therapy 5Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 2Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 3Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 4(Date:11/23/2009)..., EXTON,Pa.,Nov.23/PRNewswire/--BioTrendsResearch... Feraheme report,thesecondinamulti-phasesyndicate...IVironproduct,Feraheme,throughthefirstsixmonthsofp...titativeinformationfrom50uniqueNephrologistsandqua...strialanduseofFeraheme,obstaclestouse,reasonstouse...
(Date:11/23/2009)..., WALTHAM,Mass.,Nov.23/PRNewswire/--ProteonTherap...yofitsleadproduct,PRT-201,inend-stagerenaldisease(...t(AVG)creation.TheAVGstudyrepresentsProteon,ssecon...lyannouncingtheinitiationofaPhase1/2studyofPRT-201...tula(AVF)creationearlierthisyear.Proteonalsoannoun...
(Date:11/23/2009)..., SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswire-Firs...hatDr.TedW.LoveandDr.DavidC.U,Prichardhaveagreedto...ftheproposedmergerbetweenAnesivaandArcionTherapeut...tescheduledtotakeplaceatthepreviouslyannouncedAnes...ber3,2009at9:00a.m.PSTat400OysterPoint,Suite107A,S...
Breaking Medicine Technology:Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Partnership for Prescription Assistance Prepared to Help Idaho Workers Hurt by Recession 47971 1Partnership for Prescription Assistance Prepared to Help Idaho Workers Hurt by Recession 47971 2Partnership for Prescription Assistance Prepared to Help Idaho Workers Hurt by Recession 47971 3AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 1AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 2AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 3AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 4Once Monthly Dosing 3A How Much of a Competitive Advantage is it 3F Rheumatologists Provide Insight in the Baseline Report of LaunchTrends 28TM 29 3A 47967 1Once Monthly Dosing 3A How Much of a Competitive Advantage is it 3F Rheumatologists Provide Insight in the Baseline Report of LaunchTrends 28TM 29 3A 47967 2SCANLISA Anti-PR3 IgG
...gy relates to the ultrasensitive measurement of Ad... cells. ATP produced by the AK reaction is measur...ogy to microbiological identification techniques, ...eads, Acolyte can measure bacteria and yeasts fast...
...a differential medium designed for the direct dete...s are incorporated for the suppression of gram-neg...d yeast. S. aureus hydrolyzes the chromogenic subs... differentiation from other gram-positive organism...
...diagnostic test cleared by the FDA and by Health C...on by methicillin resistant Staphylococcus aureus ...-MRSA test results are available in about one hour... other methods that require two to five days. By d...
Medicine Products: